Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
MW-151 by ImmunoChem Therapeutics for Cognitive Disorders: Likelihood of Approval
MW-151 is under clinical development by ImmunoChem Therapeutics and currently in Phase I for Cognitive Disorders. According to GlobalData, Phase...